Effect of Amantadine on Agitation in Critically Ill Patients with Traumatic Brain Injury

Jawaher A. Gramish, Brian J. Kopp, Asad E Patanwala

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective This study aimed to compare the presence of agitation in traumatic brain injury patients treated with amantadine with those not treated with amantadine in the intensive care unit (ICU). Methods This was a retrospective cohort study conduced in a trauma ICU of a tertiary care institution in the United States. Patients who received amantadine were compared with patients who did not receive amantadine. The primary outcome measure was the presence of agitation, defined as the Richmond Agitation Sedation Scale score of +2 or higher. Secondary comparisons included haloperidol use, benzodiazepine use, opioid use, and ICU length of stay. Results A total of 139 patients were included in the study cohort (70 patients in the amantadine group, 69 patients in the no-amantadine group). There were more patients who had agitation in the amantadine group (38% vs 14%, P = 0.018). Patients who received amantadine received more opioids in fentanyl equivalents (10.3 [interquartile range {IQR}, 6.3-20.4] μg/kg vs 7.4 [IQR, 2.1-12.6] μg/kg, P = 0.009) and had a longer ICU length of stay (4.5 [IQR, 3-10] days vs 3 [IQR, 2-5] days, P = 0.010). Haloperidol use and benzodiazepine use were similar between groups. Conclusions The early use of amantadine after traumatic brain injury may increase the risk of agitation. This could increase opioid consumption and ICU length of stay.

Original languageEnglish (US)
Pages (from-to)212-216
Number of pages5
JournalClinical Neuropharmacology
Volume40
Issue number5
DOIs
StatePublished - Sep 1 2017

Fingerprint

Amantadine
Critical Illness
Intensive Care Units
Opioid Analgesics
Length of Stay
Haloperidol
Benzodiazepines
Cohort Studies
Traumatic Brain Injury
Fentanyl
Tertiary Healthcare
Retrospective Studies
Outcome Assessment (Health Care)

Keywords

  • amantadine
  • critical care
  • critical illness
  • intensive care units
  • psychomotor agitation
  • traumatic brain injuries

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Effect of Amantadine on Agitation in Critically Ill Patients with Traumatic Brain Injury. / Gramish, Jawaher A.; Kopp, Brian J.; Patanwala, Asad E.

In: Clinical Neuropharmacology, Vol. 40, No. 5, 01.09.2017, p. 212-216.

Research output: Contribution to journalArticle

@article{69e96cdd0c6344e2b23b08908a6f109b,
title = "Effect of Amantadine on Agitation in Critically Ill Patients with Traumatic Brain Injury",
abstract = "Objective This study aimed to compare the presence of agitation in traumatic brain injury patients treated with amantadine with those not treated with amantadine in the intensive care unit (ICU). Methods This was a retrospective cohort study conduced in a trauma ICU of a tertiary care institution in the United States. Patients who received amantadine were compared with patients who did not receive amantadine. The primary outcome measure was the presence of agitation, defined as the Richmond Agitation Sedation Scale score of +2 or higher. Secondary comparisons included haloperidol use, benzodiazepine use, opioid use, and ICU length of stay. Results A total of 139 patients were included in the study cohort (70 patients in the amantadine group, 69 patients in the no-amantadine group). There were more patients who had agitation in the amantadine group (38{\%} vs 14{\%}, P = 0.018). Patients who received amantadine received more opioids in fentanyl equivalents (10.3 [interquartile range {IQR}, 6.3-20.4] μg/kg vs 7.4 [IQR, 2.1-12.6] μg/kg, P = 0.009) and had a longer ICU length of stay (4.5 [IQR, 3-10] days vs 3 [IQR, 2-5] days, P = 0.010). Haloperidol use and benzodiazepine use were similar between groups. Conclusions The early use of amantadine after traumatic brain injury may increase the risk of agitation. This could increase opioid consumption and ICU length of stay.",
keywords = "amantadine, critical care, critical illness, intensive care units, psychomotor agitation, traumatic brain injuries",
author = "Gramish, {Jawaher A.} and Kopp, {Brian J.} and Patanwala, {Asad E}",
year = "2017",
month = "9",
day = "1",
doi = "10.1097/WNF.0000000000000242",
language = "English (US)",
volume = "40",
pages = "212--216",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Effect of Amantadine on Agitation in Critically Ill Patients with Traumatic Brain Injury

AU - Gramish, Jawaher A.

AU - Kopp, Brian J.

AU - Patanwala, Asad E

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective This study aimed to compare the presence of agitation in traumatic brain injury patients treated with amantadine with those not treated with amantadine in the intensive care unit (ICU). Methods This was a retrospective cohort study conduced in a trauma ICU of a tertiary care institution in the United States. Patients who received amantadine were compared with patients who did not receive amantadine. The primary outcome measure was the presence of agitation, defined as the Richmond Agitation Sedation Scale score of +2 or higher. Secondary comparisons included haloperidol use, benzodiazepine use, opioid use, and ICU length of stay. Results A total of 139 patients were included in the study cohort (70 patients in the amantadine group, 69 patients in the no-amantadine group). There were more patients who had agitation in the amantadine group (38% vs 14%, P = 0.018). Patients who received amantadine received more opioids in fentanyl equivalents (10.3 [interquartile range {IQR}, 6.3-20.4] μg/kg vs 7.4 [IQR, 2.1-12.6] μg/kg, P = 0.009) and had a longer ICU length of stay (4.5 [IQR, 3-10] days vs 3 [IQR, 2-5] days, P = 0.010). Haloperidol use and benzodiazepine use were similar between groups. Conclusions The early use of amantadine after traumatic brain injury may increase the risk of agitation. This could increase opioid consumption and ICU length of stay.

AB - Objective This study aimed to compare the presence of agitation in traumatic brain injury patients treated with amantadine with those not treated with amantadine in the intensive care unit (ICU). Methods This was a retrospective cohort study conduced in a trauma ICU of a tertiary care institution in the United States. Patients who received amantadine were compared with patients who did not receive amantadine. The primary outcome measure was the presence of agitation, defined as the Richmond Agitation Sedation Scale score of +2 or higher. Secondary comparisons included haloperidol use, benzodiazepine use, opioid use, and ICU length of stay. Results A total of 139 patients were included in the study cohort (70 patients in the amantadine group, 69 patients in the no-amantadine group). There were more patients who had agitation in the amantadine group (38% vs 14%, P = 0.018). Patients who received amantadine received more opioids in fentanyl equivalents (10.3 [interquartile range {IQR}, 6.3-20.4] μg/kg vs 7.4 [IQR, 2.1-12.6] μg/kg, P = 0.009) and had a longer ICU length of stay (4.5 [IQR, 3-10] days vs 3 [IQR, 2-5] days, P = 0.010). Haloperidol use and benzodiazepine use were similar between groups. Conclusions The early use of amantadine after traumatic brain injury may increase the risk of agitation. This could increase opioid consumption and ICU length of stay.

KW - amantadine

KW - critical care

KW - critical illness

KW - intensive care units

KW - psychomotor agitation

KW - traumatic brain injuries

UR - http://www.scopus.com/inward/record.url?scp=85040763150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040763150&partnerID=8YFLogxK

U2 - 10.1097/WNF.0000000000000242

DO - 10.1097/WNF.0000000000000242

M3 - Article

VL - 40

SP - 212

EP - 216

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -